Citius Pharmaceuticals, Inc. (CTXR) 追踪市盈率为负值 -0.5, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 0.5 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -207.01%, 前瞻盈利收益率 192.31%. PEG 0.03 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 31/100 其中 1/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -6.9 | -0.10 | 3.40 | 0.00 | - |
| 2017 | -2.8 | 0.16 | 1.31 | 0.00 | - |
| 2018 | -2.4 | 0.06 | 1.07 | 0.00 | - |
| 2019 | -1.6 | 0.05 | 1.04 | 0.00 | - |
| 2020 | -3.9 | 0.09 | 2.02 | 0.00 | - |
| 2021 | -15.9 | -0.01 | 2.78 | 0.00 | - |
| 2022 | -8.8 | -4.12 | 2.87 | 0.00 | - |
| 2023 | -5.1 | 1.55 | 1.84 | 0.00 | - |
| 2024 | -3.7 | -0.52 | 2.07 | 0.00 | - |
| 2025 | -0.4 | 0.01 | 0.20 | 0.00 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-2.29 | $0.00 | $-8.3M | - |
| 2017 | $-1.89 | $0.00 | $-10.38M | - |
| 2018 | $-1.17 | $0.00 | $-12.54M | - |
| 2019 | $-0.77 | $0.00 | $-15.58M | - |
| 2020 | $-0.45 | $0.00 | $-17.67M | - |
| 2021 | $-0.21 | $0.00 | $-23.13M | - |
| 2022 | $-0.23 | $0.00 | $-33.64M | - |
| 2023 | $-0.22 | $0.00 | $-32.54M | - |
| 2024 | $-0.23 | $0.00 | $-39.43M | - |
| 2025 | $-3.38 | $0.00 | $-37.43M | - |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $1.66 | $1.56 – $1.76 | $78.29M | $74.49M – $82.09M | 1 |
| 2027 | $2.79 | $2.61 – $2.97 | $143.76M | $130.8M – $156.71M | 1 |
| 2028 | $2.48 | $2.23 – $2.73 | $183.68M | $174.77M – $192.59M | 2 |
| 2029 | $2.83 | $2.65 – $3.01 | $208.53M | $198.42M – $218.65M | 1 |
| 2030 | $2.96 | $2.77 – $3.15 | $221.36M | $210.62M – $232.1M | 1 |
